Want to see LGND full AI Analyst Report?
LGND Stock Chart & Stats
$300.53
-$1.62(-0.54%)
At close: 4:00 PM EDT
$300.53
-$1.62(-0.54%)
Day’s Range― - ―
52-Week Range$149.51 - $326.63
Previous CloseN/A
Volume277.03K
Average Volume (3M)481.09K
Market Cap
$5.87B
Enterprise Value$6.68K
Total Cash (Recent Filing)$1.36B
Total Debt (Recent Filing)$1.13B
Price to Earnings (P/E)29.4
Beta0.88
Next Earnings
Nov 05, 2026EPS Estimate
2.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.01
Shares Outstanding19,935,610
10 Day Avg. Volume310,228
30 Day Avg. Volume481,093
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.59
Price to Sales (P/S)13.64
P/FCF Ratio74.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$350.86Price Target Upside16.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)9.26
Revenue Forecast (FY)$290.22M
Bulls Say, Bears Say
Bulls Say
Royalty/licensing Model With High MarginsLigand's partner-centric royalty and licensing model produces recurring, high-margin cash flows and operating leverage. Durable royalty receipts reduce commercial execution risk, supporting sustained profitability and cash generation that can fund acquisitions and shareholder returns over multiple years.
Transformational XOMA Acquisition Expands PortfolioThe XOMA deal materially diversifies and deepens Ligand's royalty base, increasing late-stage and commercial exposure and adding ~$2.3B of disclosed milestone upside plus tax assets. This strengthens multi-year revenue visibility and reduces single-asset concentration risk across Ligand's royalty portfolio.
Strong Liquidity And Cash-flow OutlookSubstantial low-cost financing plus robust operating cash flow guidance materially increases financial flexibility to pursue accretive royalties, absorb integration costs, and fund milestones. This durable liquidity base supports growth strategy and reduces refinancing risk over the next several years.
Bears Say
Elevated Balance-sheet LeverageDebt exceeding equity raises financing and covenant risk, reducing flexibility if royalties or milestone timing underperform. Higher leverage increases interest and redemption obligations on convertibles and can constrain future M&A or share-repurchase optionality if earnings normalize lower.
Binary Clinical And Timing Risk In PipelineA portfolio with numerous upcoming pivotal readouts and an FDA-required Phase III creates sustained binary risk that can defer or eliminate milestone and royalty cash. These development and regulatory uncertainties may materially shift multi-quarter cash flows and revenue recognition timing.
Accounting Complexity And Cash-flow VariabilityComplex recognition rules for financial royalties can obscure true economic cash generation and create earnings timing differences. Combined with historical free-cash-flow swings, this reduces predictability of distributable cash and complicates planning for acquisitions and shareholder returns over the medium term.
Ligand Pharma News
LGND FAQ
What was Ligand Pharmaceuticals Inc’s price range in the past 12 months?
Ligand Pharmaceuticals Inc lowest stock price was $149.51 and its highest was $326.63 in the past 12 months.
What is Ligand Pharmaceuticals Inc’s market cap?
Ligand Pharmaceuticals Inc’s market cap is $5.87B.
When is Ligand Pharmaceuticals Inc’s upcoming earnings report date?
Ligand Pharmaceuticals Inc’s upcoming earnings report date is Nov 05, 2026 which is in 79 days.
How were Ligand Pharmaceuticals Inc’s earnings last quarter?
Ligand Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.36.
Is Ligand Pharmaceuticals Inc overvalued?
According to Wall Street analysts Ligand Pharmaceuticals Inc’s price is currently Undervalued.
Does Ligand Pharmaceuticals Inc pay dividends?
Ligand Pharmaceuticals Inc pays a Notavailable dividend of $0.456 which represents an annual dividend yield of N/A. See more information on Ligand Pharmaceuticals Inc dividends here
What is Ligand Pharmaceuticals Inc’s EPS estimate?
Ligand Pharmaceuticals Inc’s EPS estimate is 2.36.
How many shares outstanding does Ligand Pharmaceuticals Inc have?
Ligand Pharmaceuticals Inc has 19,935,610 shares outstanding.
What happened to Ligand Pharmaceuticals Inc’s price movement after its last earnings report?
Ligand Pharmaceuticals Inc reported an EPS of $2.37 in its last earnings report, beating expectations of $2.01. Following the earnings report the stock price went down -0.803%.
Which hedge fund is a major shareholder of Ligand Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in LGND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$350.86 (16.75% Upside)
$350.86 (16.75% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 14.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
130.43%
Trailing 12-Months
Company Description
Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
LGND Company Deck
LGND Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and financial momentum: robust top-line and EPS growth, significant cash flow generation, completion of an accretive and scalable acquisition (XOMA), and successful low-cost financing that materially strengthens capital flexibility. Manageable near-term challenges include a product sales decline (Kyprolis), one-time charges, accounting complexity from increased financial royalty assets, and some timing risk from an FDA recommendation requiring a Phase III for PSC. On balance, the company presented multiple clear growth drivers and disciplined capital deployment that outweigh the identified risks.View all LGND earnings summariesLGND Stock 12 Month Forecast
Average Price Target
$350.86
▲(16.75% Upside)
Technical Analysis
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
2.54% Insiders
46.26% Mutual Funds
19.92% Other Institutional Investors
2.84% Public Companies and
Individual Investors